Lundbeck Starts Clinical Phase IIa With Lu AA24493 (cEPO) In Friedreich's Ataxia In A Study Also...

Nov 7, 2009
 

H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and tolerability and to explore... [read full story]                    

powered by
Add Comment
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies